SCHEMBL2902633

SCHEMBL2902633

CN1CCC(NCC(c2ccccc2)c2c[nH]nc2-c2ccccc2)C1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 1/20 0.37
ADRB2 P07550 2/20 0.36
ADRB1 P08588 2/20 0.36
ADRB3 P13945 2/20 0.36
SLC6A2 P23975 2/20 0.34
SLC6A3 Q01959 2/20 0.34
SLC6A4 P31645 1/20 0.34
HRH3 Q9Y5N1 2/20 0.34
CHRM2 P08172 1/20 0.34
HTR1A P08908 1/20 0.34
ADRA2A P08913 1/20 0.34
CYP2D6 P10635 1/20 0.34
CHRM1 P11229 1/20 0.34
DRD1 P21728 1/20 0.34
ADRA1A P35348 1/20 0.34
OPRM1 P35372 1/20 0.34
DRD3 P35462 1/20 0.34
KCNH2 Q12809 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2904868 0.87 CHRM3 (0.37) BACE1ADRB2ADRB1ADRB3MEN1
SCHEMBL2909769 0.86 ADRB2 (0.35) BACE1ADRB2ADRB1ADRB3MEN1
SCHEMBL2904637 0.78 TP53 (0.33) HRH3HTR1AMEN1KMT2AMAPK1
SCHEMBL2904850 0.75 NTRK1 (0.34) KCNH2MEN1KMT2AMAPK1FLT3
SCHEMBL2902618 0.73 MCHR1 (0.38) SLC6A2SLC6A3SLC6A4HRH3CHRM2
SCHEMBL31269781 0.71 KDM4E (0.55) ADRB2ADRB1ADRB3SLC6A2SLC6A3
SCHEMBL2909897 0.69 KCNH2 (0.56) SLC6A2SLC6A3SLC6A4HRH3CHRM2
SCHEMBL11727639 0.67 ACHE (0.65) BACE1MEN1KMT2A
SCHEMBL2908475 0.65 KCNA3 (0.36) OPRM1MEN1KMT2AMAPK1PDPK1
SCHEMBL16156938 0.65 ALOX15 (0.39) KMT2AMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1611107-B1 1,3,4-SUBSTITUTED PYRAZOLES FOR USE AS 5-HT RECEPTOR ANTAGONISTS IN THE TREATMENT OF PSYCHOSES AND NEUROLOGICAL DISORDERS MERCK PATENT GMBH (DE) 2010-08-18 EP claimed
US-7566709-B2 1,3,4-Substituted pyrazoles as 5-HT receptor antagonists for the treatment of psychoses and neurological disorders MERCK PATENT GMBH (DE) 2009-07-28 US disclosed
US-20070105871-A1 1,3,4-Substituted pyrazoles as 5-ht receptor antagonists for the treatment of psychoses and neurological disorders MERCK PATENT GMBH (DE) 2007-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105871-A1 1,3,4-Substituted pyrazoles as 5-ht receptor antagonists for the treatment of psychoses and neurological disorders HTR1A, HTR1D, HTR5A BACE1 1069/4885ADRB2 117/4885ADRB1 98/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.